Now showing items 1-3 of 3

    • Implementing the EffTox dose-finding design in the Matchpoint trial. 

      Brock, K; Billingham, L; Copland, M; Siddique, S; Sirovica, M; Yap, C (2017-07-20)
      The Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic transformation ...
    • Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. 

      Wagner, AJ; Banerji, U; Mahipal, A; Somaiah, N; Hirsch, H; Fancourt, C; Johnson-Levonas, AO; Lam, R; Meister, AK; Russo, G; Knox, CD; Rose, S; Hong, DS (American Society of Clinical Oncology, 2017-04-20)
      Purpose To evaluate MK-8242 in patients with wild-type TP53 advanced solid tumors. Patients and Methods MK-8242 was administered orally twice a day on days 1 to 7 in 21-day cycles. The recommended phase II dose (RP2D) was ...
    • Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. 

      Wagner, AJ; Banerji, U; Mahipal, A; Somaiah, N; Hirsch, H; Fancourt, C; Johnson-Levonas, AO; Lam, R; Meister, AK; Russo, G; Knox, CD; Rose, S; Hong, DS (2017-04)
      Purpose To evaluate MK-8242 in patients with wild-type TP53 advanced solid tumors. Patients and Methods MK-8242 was administered orally twice a day on days 1 to 7 in 21-day cycles. The recommended phase II dose (RP2D) was ...